The Pill and the Planet: Medicine, Longevity, and the New Pharmaceutical Exposome
Professor Ian Mudway
12th May 2026

The 100-Year Pivot: From Rescue to Maintenance

Modern medicine was built in the long aftermath of the Age of Pestilence. We are now nearing the centenary of Alexander Fleming's 1928 discovery of penicillin, a breakthrough that altered humanity's relationship with death. Before the antibiotic era, life was punctuated by acute crises. Survival was uncertain, and ordinary infections could become fatal with terrifying speed. Vaccines deepened that transformation by securing the childhoods of billions. In little more than a century, we moved from a world in which parents expected to bury children to one in which survival became the statistical norm.

Yet the transition into the age of degenerative disease demanded more than rescue. It required the continuous high-technology maintenance of failing systems. The mid-century refinement of insulin transformed a once-fatal diagnosis into a lifelong manageable condition. The 1960s brought beta-blockers and later statins. These enabled clinicians to reduce cardiovascular risk chemically and at scale. Chemotherapy meanwhile converted many cancers from immediate death sentences into chronic conditions of management.

These advances shifted the axis of medicine from rescue to maintenance. We no longer merely survive infection; increasingly, we manage health as an ongoing regimen. That is the success paradox at the centre of this talk. We extended life by building a model of care that rarely ends, and in doing so we created a new ecological condition: a world in which drugs and their residues now circulate through bodies, households, animals, wastewater systems, and ecosystems. The body, once imagined as largely self-sustaining, now often depends on monitoring, intervention, and a lifelong pharmaceutical supply chain.

The Pharmaceuticalisation of the Life Cycle

This subscription model is not confined to pathology. Increasingly it extends to the management of the human life course itself. The 1960 approval of the oral contraceptive pill was a social revolution built on a chemical foundation. It helped decouple sex from reproduction and expanded the autonomy of millions. Yet every emancipatory technology carries material consequences. In this case the social victory also produced a persistent hormonal footprint.

Consider Sophie, aged 26. Her contraceptive medication contains synthetic oestrogens such as ethinylestradiol. These compounds can pass through wastewater treatment systems and enter aquatic environments, where they are associated with endocrine disruption in fish. The point is not to moralise individual use, but to recognise a systemic externality. Reproductive freedom for humans can carry reproductive costs for waterways when infrastructures are not designed to intercept pharmaceutical residues.

The pattern continues through middle age in the pharmaceutical management of the human psyche. Over recent decades, treatment has expanded beyond acute psychiatric crisis towards the long-term regulation of mood and affect. Selective serotonin reuptake inhibitors, including fluoxetine, have become emblematic of this shift. Some of these compounds and their metabolites persist in aquatic environments, where they have been associated with altered behaviour in fish and other vertebrates. The broader point is not that mental health treatment is illegitimate, but that the chemical management of distress can produce environmental effects that remain largely absent from clinical and public debate.

The cycle extends further through the menopausal bridge. Hormone replacement therapy can ease the transition of menopause and preserve quality of life. Yet these benefits are also chemically mediated and residues persist beyond the body that used them. We extend healthy middle age in part by extending our chemical presence in the wider environment.

The Industrial Burden of Pharmaceutical Life

To sustain this demographic achievement, we have built a pharmaceutical infrastructure with a formidable ecological rucksack. A 2025 analysis by Hagenaars and colleagues reported that the global greenhouse-gas footprint of pharmaceutical consumption and production grew by 77 per cent between 1995 and 2019. In other words, the environmental cost of medicine is no longer marginal to modern health care. It is built into the way longevity is now delivered.

The industry is also strikingly wasteful in material terms. For every kilogram of active pharmaceutical ingredient produced, it can generate many times that weight in waste. The technical term is the E-Factor, but the broader point is simpler: as molecules become more complex, the material cost of making medicine often rises with them.

We are now entering a new phase of pharmaceuticalisation with the rise of GLP-1 receptor agonists and related weight-loss therapies. These medicines are not simple small-molecule tablets but complex drugs whose manufacture can involve resource-intensive processes, specialised facilities, and, in some cases, temperature-controlled distribution. If such therapies become routine at population scale, their therapeutic promise will need to be assessed alongside the material demands of production, packaging, storage, and transport. The larger question is whether societies can continue to address structural problems of diet, inequality, and sedentary living primarily through industrialised therapeutic management.

The wellness industry offers no clean escape from this dilemma. Millions consume vitamins and botanicals under the impression that they are avoiding the industrial pharmaceutical complex. They are mistaken. Many supplements rely on extraction and global distribution networks that carry their own opaque environmental burdens. Whether the substance is a statin or a high-dose vitamin, the ecological question remains the same. What is manufactured and what is eventually excreted back into the environment?

The Unequal Miracle: A Geography of Toxicity

This pharmacological transition has also been profoundly unequal. Wealthier societies often enjoy the benefits of pharmaceutical longevity while displacing part of the carbon and chemical burden elsewhere. A medicine taken in the United Kingdom may have been synthesised in an industrial cluster in India or China. Precursor production and manufacturing emissions are concentrated there. In this sense affluent societies can end up importing life expectancy while exporting environmental risk.

The inequality is clinical as well as geographical. In wealthier countries clinicians increasingly confront the harms of polypharmacy among older adults. In many lower-income settings by contrast people still die for want of basic medicines. The irony is brutal. Some populations suffer from excess exposure while others suffer from absence. Both conditions are shaped by the same global system. Worse still the environmental release of antimicrobial compounds threatens a common good on which all depend. That common good is the continued efficacy of antibiotics themselves.

The Metabolic Mismatch: Excreting the Problem

The crisis deepens when medicines enter ageing bodies. Here we encounter a metabolic mismatch. Older populations consume more medicine, yet hepatic and renal clearance often decline with age. Consider Arthur, a diligent 78-year-old and a model patient. He takes his medicines exactly as prescribed. But because his body processes them less efficiently than it once did, a larger share of active compounds may persist and pass through him into wastewater systems.

Part of the difficulty lies in the interaction between drug design and ageing physiology. Many medicines are formulated to remain active in the body long enough to deliver sustained therapeutic effect. When such compounds meet declining renal or hepatic function in older adults, a greater share may persist for longer and be excreted as active substances or metabolites. The result is not that every prescription becomes an ecological hazard in equal measure, but that large-scale, routine prescribing can have cumulative environmental consequences once ordinary excretion is repeated across whole populations.

This is the logic of pseudo-persistent pollution. Not a single catastrophic spill, but the quiet reliability of everyday chemistry. Arthur’s pill organiser becomes not merely a symbol of good adherence, but part of a diffuse infrastructure of environmental exposure. And the pattern does not stop with human patients. It extends into the domestic sphere through our pets.

Consider Leo, a much-loved Labrador. He receives antibiotics, anti-inflammatories, and flea treatments as part of ordinary care. Yet veterinary pharmaceuticals, like human ones, are biologically active compounds that do not vanish when care is administered. They are washed from fur, excreted in urine and faeces, and dispersed through households, gardens, streets, and waterways. Companion animals therefore extend the argument in an important way: they show that pharmaceutical life is no longer confined to hospitals, clinics, or even human bodies. The family pet is not a sentimental exception to pharmaceutical modernity, but one of its clearest archetypes.

Resistance and Ecological Blowback

The most alarming consequence of this chemical overspill is the acceleration of antimicrobial resistance. When sub-lethal concentrations of antibiotics and other bioactive compounds enter rivers and soils, they create evolutionary training grounds. What seems negligible at the level of an individual dose can become formidable at the level of the ecosystem.

In this contest between human invention and microbial evolution, the microbes possess the deeper timescale. They replicate faster, adapt sooner, and exchange resistance traits with astonishing efficiency. Every time active compounds from Arthur or Leo enter a system that cannot fully contain them, we enlarge the environmental theatre in which resistance can emerge. The same is true, at greater scale, in agriculture, where veterinary drugs move through livestock, manure, slurry, soils, and runoff into wider ecological systems.

This is the deeper irony of pharmaceutical modernity. The very compounds that extended life expectancy and transformed medicine can, under conditions of chronic environmental release, help to reshape the ecological and evolutionary conditions in which infection is managed. The problem is not simply misuse in the clinic; it is also persistent exposure beyond it. Modern pharmacology did not fail. It succeeded at such scale that its residues now help to shape microbial futures.

The Second Transition: A New Social Contract

How then do we sustain both a healthy ageing population and a liveable planet? We need a second transition in medicine: not a retreat from pharmaceuticals, but a more mature settlement between prevention, treatment, and ecological responsibility. Over the past century, societies have created something historically novel: a personal and ecological pharmaceutical exposome, an accumulating field of drugs and drug metabolites that moves through bodies, households, pets, wastewater systems, and ecosystems. We now inhabit not only medicated lives, but medicated environments.

That recognition should alter our priorities. Some of the burden currently managed downstream by lifelong prescribing must be reduced upstream through prevention: healthier diets, cleaner air, safer housing, active transport, stronger public health, and forms of care that improve health without always intensifying chemical throughput. This does not mean abandoning treatment or romanticising a pre-pharmaceutical past. It means restoring proportion. The goal should be balance: prevention where prevention is possible, management where management is necessary, and stewardship everywhere.

Thomas McKeown, the British physician and historian of medicine, was right to remind us that health is shaped by the conditions in which people live. In the twenty-first century, that insight must be extended further. The river is not outside the clinic. The household pet is not outside the system. The environment is not a passive backdrop to care. If the first medical revolution taught us how to rescue life, the next must teach us how to sustain it without corroding the ecological foundations on which long life depends.